PL2086516T3 - Przetwarzana w stanie stopionym postać użytkowa imatynibu - Google Patents

Przetwarzana w stanie stopionym postać użytkowa imatynibu

Info

Publication number
PL2086516T3
PL2086516T3 PL07822402T PL07822402T PL2086516T3 PL 2086516 T3 PL2086516 T3 PL 2086516T3 PL 07822402 T PL07822402 T PL 07822402T PL 07822402 T PL07822402 T PL 07822402T PL 2086516 T3 PL2086516 T3 PL 2086516T3
Authority
PL
Poland
Prior art keywords
melt
processed
dosage form
imatinib
imatinib dosage
Prior art date
Application number
PL07822402T
Other languages
English (en)
Inventor
Jörg Breitenbach
Norbert Steiger
Harald Hach
Ulrich Westedt
Martin Knobloch
Ralf Altenburger
Nicoletta Loggia
Jörg Ogorka
Original Assignee
Abbvie Deutschland
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland, Novartis Ag filed Critical Abbvie Deutschland
Publication of PL2086516T3 publication Critical patent/PL2086516T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
PL07822402T 2006-11-09 2007-11-08 Przetwarzana w stanie stopionym postać użytkowa imatynibu PL2086516T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06023367A EP1920767A1 (en) 2006-11-09 2006-11-09 Melt-processed imatinib dosage form
PCT/EP2007/062100 WO2008055965A1 (en) 2006-11-09 2007-11-08 Melt-processed imatinib dosage form
EP07822402.9A EP2086516B1 (en) 2006-11-09 2007-11-08 Melt-processed imatinib dosage form

Publications (1)

Publication Number Publication Date
PL2086516T3 true PL2086516T3 (pl) 2016-08-31

Family

ID=38291110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07822402T PL2086516T3 (pl) 2006-11-09 2007-11-08 Przetwarzana w stanie stopionym postać użytkowa imatynibu

Country Status (13)

Country Link
US (1) US8841303B2 (pl)
EP (2) EP1920767A1 (pl)
JP (1) JP5280369B2 (pl)
CN (3) CN101594851B (pl)
AU (1) AU2007316557B2 (pl)
BR (2) BRPI0718523B8 (pl)
CA (1) CA2668775C (pl)
ES (1) ES2565036T3 (pl)
MX (1) MX2009004858A (pl)
PL (1) PL2086516T3 (pl)
RU (1) RU2468788C2 (pl)
WO (1) WO2008055965A1 (pl)
ZA (1) ZA200903929B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
US9216172B2 (en) 2011-08-04 2015-12-22 National Cancer Center Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
MX2014006201A (es) 2011-11-24 2014-12-05 Imuneks Farma Ilaç Sanayi Ve Ticaret A S Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
CA2860932C (en) 2012-01-13 2021-02-16 Magnus Brisander A pharmaceutical composition comprising stable, amorphous hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component
CN103301067B (zh) * 2012-03-15 2018-09-11 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
CN106074554A (zh) * 2015-04-27 2016-11-09 陈骏英 一种用于治疗食管癌的药物及使用方法
CN104888228A (zh) * 2015-05-29 2015-09-09 连云港杰瑞药业有限公司 一种甲苯磺酸索拉非尼固体分散体及其制备方法
CN105126111A (zh) * 2015-09-30 2015-12-09 清华大学 提高索拉非尼生物利用度的制剂
CN106974890A (zh) * 2016-01-15 2017-07-25 常州方楠医药技术有限公司 一种无定型舒尼替尼l-苹果酸盐与药用辅料的固体分散体及其制备方法
CN109475553A (zh) * 2016-03-17 2019-03-15 太阳制药工业公司 尼洛替尼的药物组合物
CN107157941B (zh) * 2017-05-16 2020-12-25 北京化工大学 一种达沙替尼纳米制剂及其制备方法
CN110801434A (zh) * 2019-10-31 2020-02-18 金华职业技术学院 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法
WO2021150981A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
CN112294971B (zh) * 2020-02-20 2022-02-01 深圳市泰力生物医药有限公司 具有改进的溶解性的尼洛替尼组合物
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114916221B (zh) * 2020-12-07 2024-01-30 天津睿创康泰生物技术有限公司 一种高生物利用度的索拉非尼药物组合物及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384661A (en) * 1982-04-07 1983-05-24 Page Edward H Aerosol water-based paint compositions
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
EP1067910B1 (en) * 1998-04-03 2004-05-26 Egalet A/S Controlled release composition
DE19929361A1 (de) * 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
AU784340B2 (en) * 1999-12-23 2006-03-16 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
RU2231015C1 (ru) * 2002-10-03 2004-06-20 Федеральное Государственное унитарное предприятие "Государственное научно-производственное предприятие "Сплав" Устройство угловой стабилизации реактивного снаряда
EP1594468A2 (en) * 2003-02-03 2005-11-16 Novartis AG Process for preparing a solid dispersion pharmaceutical product
KR100976076B1 (ko) * 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
CN101232870A (zh) * 2005-06-03 2008-07-30 伊兰制药国际有限公司 纳米微粒甲磺酸伊马替尼制剂
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form

Also Published As

Publication number Publication date
CN101594852A (zh) 2009-12-02
US8841303B2 (en) 2014-09-23
RU2468788C2 (ru) 2012-12-10
CN101594851A (zh) 2009-12-02
JP2010509288A (ja) 2010-03-25
RU2009121653A (ru) 2010-12-20
AU2007316557B2 (en) 2013-10-31
WO2008055965A1 (en) 2008-05-15
AU2007316557A1 (en) 2008-05-15
CN101594852B (zh) 2013-04-03
BRPI0718523B8 (pt) 2022-09-13
BRPI0718523B1 (pt) 2022-03-03
EP1920767A1 (en) 2008-05-14
CN102512680A (zh) 2012-06-27
BRPI0718521A2 (pt) 2013-11-19
US20100240672A1 (en) 2010-09-23
EP2086516A1 (en) 2009-08-12
ES2565036T3 (es) 2016-03-30
CN101594851B (zh) 2013-01-02
JP5280369B2 (ja) 2013-09-04
BRPI0718523A2 (pt) 2013-11-19
MX2009004858A (es) 2009-05-21
EP2086516B1 (en) 2016-01-06
ZA200903929B (en) 2010-03-31
CA2668775A1 (en) 2008-05-15
CA2668775C (en) 2014-08-12

Similar Documents

Publication Publication Date Title
PL2086516T3 (pl) Przetwarzana w stanie stopionym postać użytkowa imatynibu
IL194762A0 (en) Pharmaceutical compounds
GB0608820D0 (en) Pharmaceutical compounds
EP2015856A4 (en) MUSICAL INTERACTION DEVICES
GB0616574D0 (en) Compounds
GB0513984D0 (en) Dosage form
IL194366A0 (en) Solid dosage formulations
IL197325A0 (en) Imatinib compositions
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
PL1829532T3 (pl) Stabilna, stała postać dawkowania zawierająca desmopresynę
GB0616794D0 (en) Solid dosage form
EP2082022A4 (en) COMPOUNDS
EP1753400A4 (en) PHARMACEUTICAL FOR ZIPRASIDONE
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0608184D0 (en) Pharmaceutical compounds
GB0608176D0 (en) Pharmaceutical Compounds
GB0608264D0 (en) Pharmaceutical compounds
EP1973905A4 (en) COMPOUNDS
GB0622892D0 (en) Pharmaceutical compounds
GB0608175D0 (en) Pharmaceutical Compounds
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP2016069A4 (en) BISPYRIDINIUMVERBINDUNGEN
GB0600427D0 (en) Compounds
GB0625682D0 (en) Pharmaceutical compounds
GB0522989D0 (en) Dosage form